ExtraCorporeal life support for Cardiac ARrest in patients with post cardiac arrest syndrome: The ECCAR study.


Journal

Archives of cardiovascular diseases
ISSN: 1875-2128
Titre abrégé: Arch Cardiovasc Dis
Pays: Netherlands
ID NLM: 101465655

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 11 06 2018
revised: 05 08 2018
accepted: 04 11 2018
pubmed: 8 1 2019
medline: 14 6 2019
entrez: 8 1 2019
Statut: ppublish

Résumé

Post cardiac arrest shock (PCAS) occurring after resuscitated cardiac arrest (CA) is a main cause of early death. Extracorporeal life support (ECLS) could be useful pending recovery from myocardial failure. To describe our PCAS population, and the factors associated with initiation of ECLS. This analysis included 921 patients admitted to two intensive care units between 2005 and 2014 for CA and PCAS; 43 of these patients had ECLS initiated. Neurological and ECLS-related outcomes were gathered retrospectively. The 43 patients treated with ECLS were predominantly (70%) young males with evidence of myocardial infarction on coronary angiography. ECLS was initiated in patients with severe cardiovascular dysfunction (median left ventricular ejection fraction 15% [interquartile range 10-25%]), a median of 9hours [interquartile range 6-16hours] after the CA. At 1 year, eight patients (19%) had survived without neurological disability. Blood lactate and coronary aetiology were associated with neurological outcomes. Logistic regression conducted using 878 controls with PCAS identified age>62 years, location of CA, use of a high dose of adrenaline (>3mg) and blood lactate and serum creatinine concentrations (>5mmol/L and>109μmol/L, respectively) as risk factors for initiation of ECLS. ECLS, as a salvage therapy for PCAS, could be an acceptable alternative for highly-selected patients.

Sections du résumé

BACKGROUND BACKGROUND
Post cardiac arrest shock (PCAS) occurring after resuscitated cardiac arrest (CA) is a main cause of early death. Extracorporeal life support (ECLS) could be useful pending recovery from myocardial failure.
AIM OBJECTIVE
To describe our PCAS population, and the factors associated with initiation of ECLS.
METHODS METHODS
This analysis included 921 patients admitted to two intensive care units between 2005 and 2014 for CA and PCAS; 43 of these patients had ECLS initiated. Neurological and ECLS-related outcomes were gathered retrospectively.
RESULTS RESULTS
The 43 patients treated with ECLS were predominantly (70%) young males with evidence of myocardial infarction on coronary angiography. ECLS was initiated in patients with severe cardiovascular dysfunction (median left ventricular ejection fraction 15% [interquartile range 10-25%]), a median of 9hours [interquartile range 6-16hours] after the CA. At 1 year, eight patients (19%) had survived without neurological disability. Blood lactate and coronary aetiology were associated with neurological outcomes. Logistic regression conducted using 878 controls with PCAS identified age>62 years, location of CA, use of a high dose of adrenaline (>3mg) and blood lactate and serum creatinine concentrations (>5mmol/L and>109μmol/L, respectively) as risk factors for initiation of ECLS.
CONCLUSIONS CONCLUSIONS
ECLS, as a salvage therapy for PCAS, could be an acceptable alternative for highly-selected patients.

Identifiants

pubmed: 30612896
pii: S1875-2136(18)30199-2
doi: 10.1016/j.acvd.2018.11.005
pii:
doi:

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

253-260

Informations de copyright

Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Auteurs

Adrien Bouglé (A)

Medical Intensive Care Unit, Cochin University Hospital, AP-HP, 75014 Paris, France; Paris V University, 75006 Paris, France. Electronic address: adrien.bougle@aphp.fr.

Arthur Le Gall (A)

Medical Intensive Care Unit, Cochin University Hospital, AP-HP, 75014 Paris, France; Paris V University, 75006 Paris, France.

Florence Dumas (F)

Paris V University, 75006 Paris, France; Emergency Department, Cochin University Hospital, AP-HP, 75014 Paris, France; Inserm UMR-S970, Paris Cardiovascular Research Centre, 75908 Paris, France.

Guillaume Geri (G)

Medical Intensive Care Unit, Cochin University Hospital, AP-HP, 75014 Paris, France; Paris V University, 75006 Paris, France; Inserm UMR-S970, Paris Cardiovascular Research Centre, 75908 Paris, France.

Isabelle Malissin (I)

Medical and Toxicologic Intensive Care Unit, Lariboisière University Hospital, AP-HP, 75010 Paris, France; Paris VII University, 75013 Paris, France.

Sebastian Voicu (S)

Medical and Toxicologic Intensive Care Unit, Lariboisière University Hospital, AP-HP, 75010 Paris, France; Paris VII University, 75013 Paris, France.

Bruno Mégarbane (B)

Medical and Toxicologic Intensive Care Unit, Lariboisière University Hospital, AP-HP, 75010 Paris, France; Paris VII University, 75013 Paris, France.

Alain Cariou (A)

Medical Intensive Care Unit, Cochin University Hospital, AP-HP, 75014 Paris, France; Paris V University, 75006 Paris, France; Inserm UMR-S970, Paris Cardiovascular Research Centre, 75908 Paris, France.

Nicolas Deye (N)

Medical and Toxicologic Intensive Care Unit, Lariboisière University Hospital, AP-HP, 75010 Paris, France; Paris VII University, 75013 Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH